<SEC-DOCUMENT>0001279569-19-000033.txt : 20190108
<SEC-HEADER>0001279569-19-000033.hdr.sgml : 20190108
<ACCEPTANCE-DATETIME>20190108111600
ACCESSION NUMBER:		0001279569-19-000033
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180108
FILED AS OF DATE:		20190108
DATE AS OF CHANGE:		20190108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AURORA CANNABIS INC
		CENTRAL INDEX KEY:			0001683541
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38691
		FILM NUMBER:		19514980

	BUSINESS ADDRESS:	
		STREET 1:		500 - 10355 JASPER AVENUE
		CITY:			EDMONTON
		STATE:			A0
		ZIP:			T5J 1Y6
		BUSINESS PHONE:		604-362-5207

	MAIL ADDRESS:	
		STREET 1:		900 - 510 SEYMOUR STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6B 1V5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>aurora_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED
STATES</B></FONT><BR>
<FONT STYLE="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION</B></FONT><BR>
<B>Washington, D.C. 20549</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><B>RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">For the month of <B>January 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Commission File No. <B>001-38691</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><FONT STYLE="font-size: 24pt"><B>AURORA
CANNABIS INC.</B></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 70%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><FONT STYLE="font-size: 24pt"></FONT><BR>
<FONT STYLE="font-size: 10pt">(Translation of registrant's name into English)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>500 - 10355 Jasper Avenue</B><BR>
<B>Edmonton, Alberta, T5J 1Y6, Canada</B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 70%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><B></B><BR>
(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center">Form 20-F &#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B> Form
40-F&nbsp;&nbsp;&#9746;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) &nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) &nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>SUBMITTED HEREWITH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; font: 12pt Times New Roman, Times, Serif; text-align: center; vertical-align: middle; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibits</B></FONT></TD>
    <TD STYLE="width: 2%"></TD>
    <TD STYLE="width: 90%; font: 12pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Description&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt"><A HREF="ex991.htm">99.1</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: bold 13pt Arial, Helvetica, Sans-Serif; text-align: left; text-transform: uppercase"><A HREF="ex991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">News
Release dated January 8, 2019</FONT></A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center"><A HREF="ex991.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></A></TD>
    <TD></TD>
    <TD STYLE="font: 10pt Arial, Helvetica, Sans-Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex991.htm"></A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0"><B>AURORA CANNABIS INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">/s/ <I>Glen Ibbott</I></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 50%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0"><I></I><BR>
Glen Ibbott<BR>
Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0">Date: January 8, 2019</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED JANUARY 8, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: justify">&nbsp;<IMG SRC="logo.jpg" ALT=""></P>



<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 9.45pt 109.85pt 0 109.7pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="font: bold 24pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Aurora Cannabis Provides Guidance for
the Second Quarter of Fiscal 2019, Anticipating Net Revenues of $50M to $55M</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; text-align: center; margin-right: 0; margin-left: 0"><B>Company Provides Production
Guidance and is Tracking to Achieve Positive EBITDA in Second Calendar Quarter 2019 </B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">TSX | NYSE: ACB</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">EDMONTON, Jan.&nbsp;8, 2019 /CNW/ -&nbsp;Aurora
Cannabis Inc. (&quot;Aurora&quot; or the &quot;Company&quot;) (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) today provided
an expected revenue range for the second quarter of the Company's Fiscal 2019 (&quot;Q2 2019&quot;), the period ended December
31, 2018. Full results will be published on Monday, February 11, 2019 pre-market, followed by a conference call later that day,
details for which can be found at the end of this release.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Based on preliminary (unaudited) results, the
Company anticipates revenues for Q2 2019 of between $50 million and $55 million (net of excise taxes), compared to $11.7 million
for the same quarter in the prior year, and compared to $29.7 million for the previous quarter ended September 30, 2018 (&quot;Q1
2019&quot;). The results reflect an anticipated revenue growth rate in excess of 327% compared to Q2 2018 and in excess of 68%
compared to Q1 2019.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Revenue growth for the quarter was driven by
the Company's strong position in the adult consumer use market in Canada, continued shipments of medical cannabis to Aurora's expanding
base of approximately 71,000 patients in Canada, and relatively stable, supply restricted shipments, to its growing international
markets.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The Company continues to ramp its production
capacity up from 70,000 kg / annum as reported in November 2018, to approximately 100,000 kg / annum today and reaffirms its expectation
to achieve at least 150,000 kg / annum of production capacity within the first calendar quarter of 2019 (&quot;Q3 2019&quot;).
Aurora defines production capacity as representing all planted rooms approved by Health Canada, factoring in anticipated harvests
at maturity annualized for the following twelve (12) month period, based on an average historical yield per plant.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Based on its current production capacity of
100,000 kg / annum and the Company's cultivation and harvest schedules, Aurora expects its production available for sale will be
approximately 25,000 kg equivalent of cannabis in the Company's Q4 2019, the period ending June 30, 2019, with continued production
volume increases in subsequent quarters.&nbsp;Aurora defines production available for sale as representing the Company's production
capacity harvested and processed into a final product for sale. Paired with strong current and future anticipated demand for the
Company's products across its different market segments, this is expected to result in continued strong revenue growth.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The market introduction of higher-margin products,
such as softgels, as well as its vape-ready CBD oil cartridge product Aurora Cloud, is expected to contribute to sustained strong
gross margins during fiscal 2019.&nbsp;Additionally, Aurora is looking forward to the upcoming finalization of the draft regulations
which will allow derivative, higher margin products such as vape pens, beverages, and edibles to be sold in the Canadian adult
use market during 2019.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Additionally, disciplined cost management is
anticipated to result in SG&amp;A costs to be roughly consistent with the previous quarter, including a full quarter of costs related
to all integrated subsidiaries in MedReleaf, Anandia and Agropro. Consequently, management believes the combination of substantial
revenue growth and disciplined cost management positions the Company well to achieve sustained positive EBITDA beginning in Fiscal
Q4 2019 (Calendar Q2 2019).</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The preliminary estimated financial results
and other data for the three months ended December 31, 2018 set forth above are subject to the completion of the Company's financial
closing procedures. These data have been prepared by, and is the responsibility of, the Company's management, and was approved
by management on January 7, 2019. Aurora's independent registered public accounting firm, KPMG LLP, has not audited, reviewed or
performed any procedures with respect to the accompanying preliminary financial results and other data, and accordingly does not
express an opinion or any other form of assurance with respect thereto. The Company currently expects that its final results of
operations and other data will be consistent with the estimates set forth above, but such estimates are preliminary and Aurora's
actual results of operations and other data could differ materially from these estimates due to the completion of its financial
closing procedures, final adjustments and other developments that may arise between now and the time such unaudited interim consolidated
financial statements for the three months ended December 31, 2018 are issued.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Management Commentary</B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">&quot;Aurora continues to execute effectively
across all market segments, as demonstrated by its revenue growth anticipated to exceed 68% as compared to last quarter, supported
by continued strong performance in the Canadian adult consumer use market,&quot; said Terry Booth, CEO of Aurora. &quot;Our consistent
and high-quality production continues to significantly ramp up as expected, fueling even further growth. Going forward, we see
sustained strong demand from the adult usage market, as evidenced by public statements from the Canadian provinces, as well as
strong patient-driven demand for medical cannabis in Canada and abroad. These factors, together with our focus on disciplined management
of operating expenses, and our growing portfolio of higher margin products, put us in a position to rapidly achieve positive EBITDA
within the next two quarters.&quot;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Facilities Video </B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">The Company today released updated video of
its production facilities, including Aurora Sky, Aurora Eau, Aurora Vie, MedReleaf Bradford, Aurora Mountain, ICC Labs, and Agropro.
The footage demonstrates the technologically advanced nature of Aurora's diverse production assets, as well as the mature nature
of its operations. The video material may be viewed here: https://www.dropbox.com/s/o517edo5l9n2v5r/AURORA_FACILITIES_V06.mp4?dl=0</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Second Quarter 2019 Conference Call</B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Aurora has scheduled its conference call to
discuss the results for its second quarter ended December 31, 2018, which will be released on Monday, February 11<SUP>th</SUP>,
2019 pre-market, The conference call will be hosted that day at 10:30 a.m. Eastern Time by Terry Booth, Chief Executive Officer,
Glen Ibbott, Chief Financial Officer, Cam Battley, Chief Corporate Officer, and Michael Singer, Chairman of the Board, followed
by a question and answer period.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt">&nbsp;</TD>
    <TD STYLE="padding-right: 6pt; padding-left: 6pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; font: 7.5pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">DATE:</FONT></TD>
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; font: 7.5pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Monday, February 11<SUP>th</SUP>, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; font: 7.5pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">TIME:</FONT></TD>
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; font: 7.5pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">10:30 a.m. Eastern Time |&nbsp;8:30 a.m. Mountain Time</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; font: 7.5pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">WEBCAST:</FONT></TD>
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; font: 7.5pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">https://bit.ly/2VvfrlA&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="font: 7.5pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">REPLAY:</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-right: 6pt; padding-left: 6pt; font: 7.5pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(416) 849-0833 or (855) 859-2056</FONT><BR>
<FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Available until 12:00 midnight Eastern Time Monday, February 18, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; font: 7.5pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">REFERENCE NUMBER:</FONT></TD>
    <TD STYLE="padding-right: 6pt; padding-left: 6pt; font: 7.5pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">2474319</FONT></TD></TR>
</TABLE>
<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>About Aurora&nbsp;</B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Headquartered in Edmonton, Alberta, Canada
with funded capacity in excess of 500,000 kg per annum and sales and operations in 22 countries across five continents, Aurora
is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across
every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis
and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Highly differentiated from its peers, Aurora
has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate
leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale
production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are
designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs.
Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf
Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland, have achieved this level of certification.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">In addition to the Company's rapid organic
growth and strong execution on strategic M&amp;A, which to date includes 15 wholly owned subsidiary companies &ndash; MedReleaf,
CanvasRx, Peloton Pharmaceutical, Aurora Deutschland , H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses,
CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and ICC Labs &ndash; Aurora is distinguished
by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic
partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV:
HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private),
Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Aurora's Common Shares trade on the TSX and
NYSE under the symbol &quot;ACB&quot;, and are a constituent of the S&amp;P/TSX Composite Index.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">For more information about Aurora, please visit
our investor website, investor.auroramj.com&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Terry Booth, CEO<BR>
Aurora Cannabis Inc.&nbsp;</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><B>Forward looking statements&nbsp;</B></P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">This news release makes reference to certain
non-IFRS measures, including certain industry metrics. These metrics and measures are not recognized measures under IFRS do not
have meanings prescribed under IFRS and are as a result unlikely to be comparable to similar measures presented by other companies.
These measures are provided as information complimentary to those IFRS measures by providing a further understanding of our operating
results from the perspective of management. As such, these measures should not be considered in isolation or in lieu of review
of our financial information reported under IFRS. This news release uses non-IFRS measures including &quot;EBITDA&quot;, &quot;production
capacity&quot;, &quot;production available for sale&quot; and &quot;SG&amp;A&quot;.&nbsp; Production capacity and production available
for sale are commonly used operating measures in the industry but may be calculated differently compared to other companies in
the industry. These non-IFRS measures, including the industry measures, are used to provide investors with supplementary measures
of our operating performance that may not otherwise be apparent when relying solely on IFRS metrics. Definitions of the non-IFRS
measures can be found in our MD&amp;A and in this news release.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">This news release also&nbsp;includes statements
containing certain &quot;forward-looking information&quot; within the meaning of applicable securities law (&quot;forward-looking
statements&quot;). Forward-looking statements are frequently characterized by words such as &quot;plan&quot;, &quot;continue&quot;,
&quot;expect&quot;, &quot;project&quot;, &quot;intend&quot;, &quot;believe&quot;, &quot;anticipate&quot;, &quot;estimate&quot;,
&quot;may&quot;, &quot;will&quot;, &quot;potential&quot;, &quot;proposed&quot; and other similar words, or statements that certain
events or conditions &quot;may&quot; or &quot;will&quot; occur. These statements are only predictions. Various assumptions were
used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those
projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personal, the
ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued
quality of our products, customer experience and retention, the development of third party government and non-government adult-use&nbsp;
sales channels, managements estimation of consumer demand in Canada and in jurisdictions where the Company exports, expectations
of future results and expenses, the availability of additional capital to complete construction projects and facilities improvements,
the risk of successful integration of acquired business and operations, management's estimation that SG&amp;A will grow only in
proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, and the
possibility for changes in laws, rules, and regulations in the industry, as well as the risks identified under the heading &quot;Risk
Factors&quot; in the company's Annual Information Form for the financial year ended June 30, 2018 filed in Canada on SEDAR at www.sedar.com
and in the United States on Edgar under Form 40-F at www.sec.gov.&nbsp;The Company is under no obligation, and expressly disclaims
any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future
events or otherwise, except as expressly required by applicable law.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">Neither TSX nor its Regulation Services Provider
(as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this
release.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0"><IMG SRC="image_001.jpg" ALT="Cision" STYLE="height: 12px; width: 12px">View
original content to download multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-provides-guidance-for-the-second-quarter-of-fiscal-2019-anticipating-net-revenues-of-50m-to-55m-300774575.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">SOURCE Aurora Cannabis Inc.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">View original content to download multimedia:
http://www.newswire.ca/en/releases/archive/January2019/08/c6700.html</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">%CIK: 0001683541</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin: 0"><B>For further information: </B>For Media: Heather MacGregor, +1.416.509.5416,
heather.macgregor@auroramj.com; For Investors: Marc Lakmaaker, +1.647.269.5523, marc.lakmaaker@auroramj.com; Rob Kelly, +1.647.331.7228,
rob.kelly@auroramj.com; U.S. Investors: Phil Carlson / Elizabeth Barker, KCSA Strategic Communications, Phone: (212) 896-1233 /
(212) 896-1203, Email: pcarlson@kcsa.com / ebarker@kcsa.com</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CO: Aurora Cannabis Inc.</P>

<P STYLE="font: 15pt Arial, Helvetica, Sans-Serif; margin-right: 0; margin-left: 0">CNW 07:00e 08-JAN-19</P>



<P STYLE="margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ,  P# 2(  A$! Q$!_\0
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?L94\=#@5IJH50HZ 8%8TXM3DWU.BK.+I02Z>7ZG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  < )4# 2(  A$! Q$!_\0
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M[5;'PO8:7H%[H]II$TDD<-U-YC-N96VK_P!\U^@Y;DT;T9RI_P"+FY>7X?\
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MJ#XG?M5?"CX+^(AH/C/QIIV@:NT2SBUN=V[RV^ZWRK7YC^)?^4RUE_V-%O\
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BPM8^.-#O/#WB72XVT^>VU),2.D>!&X]BI _"BO=J* /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
